MicroRNAs (miRNAs) as biomarker(s) for prognosis and diagnosis of gastrointestinal (GI) cancers

Current Pharmaceutical Design

Volumn 20, Issue 33, 2014, Pages 5287-5297

  Macha, Muzafar A ^a   Seshacharyulu, Parthasarathy ^a   Krishn, Shiv Ram ^a   Pai, Priya ^a   Rachagani, Satyanarayana ^a   Jain, Maneesh ^a,b   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Gastrointestinal cancers; miRNAs; Prognosis

Indexed keywords

MICRORNA; MICRORNA 1; MICRORNA 129 1 3P; MICRORNA 129 2 3P; MICRORNA 133A; MICRORNA 133B; MICRORNA 143; MICRORNA 145; MICRORNA 150; MICRORNA 194; MICRORNA 199 1 3P; MICRORNA 200C; MICRORNA 203; MICRORNA 205; MICRORNA 20A; MICRORNA 21; MICRORNA 215; MICRORNA 223; MICRORNA 25; MICRORNA 27A; MICRORNA 31; MICRORNA 34; MICRORNA 342; MICRORNA 375; MICRORNA 378; MICRORNA 423 5P; MICRORNA LET7C; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA;

ALLELE; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INVASION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; COLUMNAR EPITHELIUM; DIGESTIVE SYSTEM CANCER; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS DYSPLASIA; ESOPHAGUS MUCOSA; GALLBLADDER CANCER; GENE OVEREXPRESSION; HELICOBACTER INFECTION; HUMAN; INTESTINE CANCER; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; UPREGULATION; GASTROINTESTINAL NEOPLASMS; GENETICS; METABOLISM; PROGNOSIS;

BIOMARKERS, TUMOR; GASTROINTESTINAL NEOPLASMS; HUMANS; MICRORNAS; PROGNOSIS;

EID: 84907689638     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140128213117     Document Type: Article

References (138)

1. Marusawa H, Jenkins BJ. Inflammation and gastrointestinal cancer: An overview. Cancer Lett 2013; 10.
2. Lumachi F, Brandes AA, Ermani M, et al. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 2000; 20: 4751-4755.
3. Tricoli JV, Jacobson JW. MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis. Cancer Res 2007; 67: 4553-4555.
4. Gartel AL, Kandel ES. miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol 2008; 18: 103-110.
5. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
6. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
7. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-7722.
8. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006; 25: 6188-6196.
9. Grady WM, Tewari M. The next thing in prognostic molecular markers: microRNA signatures of cancer. Gut 2010; 59: 706-708.
10. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
11. Jay C, Nemunaitis J, Chen P, et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007; 26: 293-300.
12. Yu SL, Chen HY, Yang PC, et al. Unique MicroRNA signature and clinical outcome of cancers. DNA Cell Biol 2007; 26: 283-292.
13. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001; 61: 6640-6648.
14. Park NJ, Zhou H, Elashoff D, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009; 15: 5473-5477.
15. Hanke M, Hoefig K, Merz H, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2010; 28: 655-661.
16. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-2092.
17. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741.
18. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009; 13: 1248-1260.
19. Blanco-Calvo M, Calvo L, Figueroa A, et al. Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel) 2012; 12: 9349-9362.
20. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
21. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
22. Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009; 2: ra81.
23. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
24. Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233.
25. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012; 37: 460-465.
26. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4: 143-159.
27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
28. Lee JH. Interventional gastroenterology: esophageal and pancreatic cancers. Semin Oncol 2005; 32: 25-28.
29. Agarwal A, Polineni R, Hussein Z, et al. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 2012; 5: 382-396.
30. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009; 15: 5744-5752.
31. Wijnhoven BP, Hussey DJ, Watson DI, et al. MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br J Surg 2010; 97: 853-861.
32. Maru DM, Singh RR, Hannah C, et al. MicroRNA-196a is a potential marker of progression during Barrett's metaplasiadysplasia-invasive adenocarcinoma sequence in esophagus. Am J Pathol 2009; 174: 1940-1948.
33. Wu X, Ajani JA, Gu J, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2013; 6: 196-205.
34. Leidner RS, Ravi L, Leahy P, et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012; 51: 473-479.
35. Kim TJ, Kim HY, Lee KW, et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009; 29: 403-421.
36. Hiyoshi Y, Kamohara H, Karashima R, et al. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915-1922.
37. Kong KL, Kwong DL, Chan TH, et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
38. Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer-implications for pathogenesis and therapy. Curr Pharm Des 2013; 19: 1211-1226.
39. Liu R, Liao J, Yang M, et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One 2012; 7: e33987.
40. Pack SD, Karkera JD, Zhuang Z, et al. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer 1999; 25: 160-168.
41. Carrasco G, Corvalan AH. Helicobacter pylori-Induced Chronic Gastritis and Assessing Risks for Gastric Cancer. Gastroenterol Res Pract 2013; 2013: 393015. doi: 10. 1155/2013/393015. Epub; %2013 Jul 29.: 393015.
42. Link A, Kupcinskas J, Wex T, et al. Macro-role of microRNA in gastric cancer. Dig Dis 2012; 30: 255-267.
43. Cai H, Yuan Y, Hao YF, et al. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 2013; 30: 452-0452.
44. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012; 10: 186. doi: 10. 1186/1479-5876-10-186.: 186-10.
45. Yu X, Luo L, Wu Y, et al. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013; 30: 365-0365.
46. Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 2013; 108: 89-92.
47. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-791.
48. Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012; 7: e41629.
49. Kim SY, Jeon TY, Choi CI, et al. Validation of Circulating miRNA Biomarkers for Predicting Lymph Node Metastasis in Gastric Cancer. J Mol Diagn 2013; 15: 661-669.
50. Teng RY, Zhou JC, Jiang ZN, et al. The relationship between Lin28 and the chemotherapy response of gastric cancer. Onco Targets Ther 2013; 6: 1341-1345.: 1341-1345.
51. Yang Q, Zhang C, Huang B, et al. Downregulation of microRNA-206 is a potent prognostic marker for patients with gastric cancer. Eur J Gastroenterol Hepatol 2013; 25: 953-957.
52. Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17: 2725-2733.
53. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
54. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
55. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154.
56. Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447.
57. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 20; 25: 2537-2545.
58. Budhu A, Jia HL, Forgues M, et al. Identification of metastasisrelated microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
59. Wang Y, Lee AT, Ma JZ, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem 2008; 283: 13205-13215.
60. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010; 107: 264-269.
61. Wong QW, Ching AK, Chan AW, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010; 16: 867-875.
62. Huang YH, Lin KH, Chen HC, et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One 2012; 7: e37188.
63. Chung GE, Yoon JH, Myung SJ, et al. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol Rep 2010; 23: 113-119.
64. Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 2013; 10.
65. Yang H, Fang F, Chang R, et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 2013; 58: 205-217.
66. Murakami Y, Tamori A, Itami S, et al. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013; 13: 99-13.
67. Zhang Y, Takahashi S, Tasaka A, et al. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 565-575.
68. Zhuo L, Liu J, Wang B, et al. Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013; 29: 555-562.
69. Lai CH, Lau WY. Gallbladder cancer-a comprehensive review. Surgeon 2008; 6: 101-110.
70. Kono H, Nakamura M, Ohtsuka T, et al. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep 2013; 30: 17-24.
71. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4: 695-706.
72. Marsh RW, Alonzo M, Bajaj S, et al. Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. J Surg Oncol 2012; 106: 332-338.
73. Chang Y, Liu C, Yang J, et al. miR-20a triggers metastasis of gallbladder carcinoma. J Hepatol 2013; 59: 518-527.
74. Jin K, Xiang Y, Tang J, et al. miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol 2013.
75. Srivastava K, Srivastava A, Mittal B. Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet 2010; 55: 495-499.
76. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442-4452.
77. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120: 1046-1054.
78. Park JK, Henry JC, Jiang J, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011; 406: 518-523.
79. Zhang S, Hao J, Xie F, et al. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011; 32: 1183-1189.
80. Yu S, Lu Z, Liu C, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70: 6015-6025.
81. Ikenaga N, Ohuchida K, Mizumoto K, et al. MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol 2010; 17: 3120-3128.
82. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297: 1901-1908.
83. Torrisani J, Bournet B, du Rieu MC, et al. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20: 831-844.
84. Watanabe S, Ueda Y, Akaboshi S, et al. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009; 174: 854-868.
85. Schultz NA, Werner J, Willenbrock H, et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 2012; 25: 1609-1622.
86. Papaconstantinou IG, Manta A, Gazouli M, et al. Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 2013; 42: 67-71.
87. Schultz NA, Andersen KK, Roslind A, et al. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer-five microRNAs in a prognostic index. World J Surg 2012; 36: 2699-2707.
88. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24: 4677-4684.
89. Munding JB, Adai AT, Maghnouj A, et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012; 131: E86-E95.
90. Dillhoff M, Liu J, Frankel W, et al. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 2008; 12: 2171-2176.
91. Dillhoff M, Wojcik SE, Bloomston M. MicroRNAs in solid tumors. J Surg Res 2009; 154: 349-354.
92. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009; 106: 4402-4407.
93. Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105: 1733-1740.
94. Ali S, Almhanna K, Chen W, et al. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res 2010; 3: 28-47.
95. Matthaei H, Wylie D, Lloyd MB, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res 2012; 18: 4713-4724.
96. Ali S, Saleh H, Sethi S, et al. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer 2012; 107: 1354-1360.
97. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
98. Li Y, VandenBoom TG, Kong D, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-tomesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
99. Giovannetti E, van d, V, Funel N, et al. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One 2012; 7: e49145.
100. Jamieson NB, Morran DC, Morton JP, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18: 534-545.
101. Li SC, Essaghir A, Martijn C, et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013; 26: 685-696.
102. Corte H, Manceau G, Blons H, et al. MicroRNA and colorectal cancer. Dig Liver Dis 2012; 44: 195-200.
103. Luo X, Burwinkel B, Tao S, et al. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 2011; 20: 1272-1286.
104. Madhavan D, Cuk K, Burwinkel B, et al. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 2013; 4: 116. doi: 10. 3389/fgene. 2013. 00116. eCollection; %2013.: 116.
105. Mazeh H, Levy Y, Mizrahi I, et al. Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J Surg Res 2013; 180: 216-221.
106. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13: 358-369.
107. Ma Y, Zhang P, Wang F, et al. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun 2012; 3: 1291. doi: 10. 1038/ncomms2276.: 1291.
108. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
109. Slaby O, Svoboda M, Fabian P, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007; 72: 397-402.
110. Kulda V, Pesta M, Topolcan O, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet 2010; 200: 154-160.
111. Nielsen BS, Jorgensen S, Fog JU, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27-38.
112. Shibuya H, Iinuma H, Shimada R, et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 2010; 79: 313-320.
113. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011; 26: 1415-1422.
114. Schee K, Boye K, Abrahamsen TW, et al. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012; 12: 505. doi: 10. 1186/1471-2407-12-505.: 505-512.
115. Wang CJ, Stratmann J, Zhou ZG, et al. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 2010; 10: 616. doi: 10. 1186/1471-2407-10-616.: 616-10.
116. Xi Y, Formentini A, Chien M, et al. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2006; 2: 113-121.: 113-121.
117. Bovell LC, Shanmugam C, Putcha BD, et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer. Clin Cancer Res 2013; 19: 3955-3965.
118. Mazeh H, Mizrahi I, Ilyayev N, et al. The Diagnostic and Prognostic Role of microRNA in Colorectal Cancer-a Comprehensive review. J Cancer 2013; 4: 281-295.
119. Vickers MM, Bar J, Gorn-Hondermann I, et al. Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease. Clin Exp Metastasis 2012; 29: 123-132.
120. Hofsli E, Sjursen W, Prestvik WS, et al. Identification of serum microRNA profiles in colon cancer. Br J Cancer 2013; 108: 1712-1719.
121. Bandres E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 19; 5: 29.: 29.
122. Ragusa M, Statello L, Maugeri M, et al. Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors. J Mol Med (Berl) 2012; 90: 1421-1438.
123. Faltejskova P, Svoboda M, Srutova K, et al. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-2666.
124. Zhang JX, Song W, Chen ZH, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol 2013; 14: 1295-1306.
125. Link A, Balaguer F, Shen Y, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-1774.
126. Yang IP, Tsai HL, Huang CW, et al. The functional significance of microRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013; 8: e66842.
127. Pizzini S, Bisognin A, Mandruzzato S, et al. Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics 2013; 14: 589.
128. Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One 2014; 9: e84686.
129. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 20; 9: 374. doi: 10. 1186/1471-2407-9-374.: 374-379.
130. Dong Y, Zhao J, Wu CW, et al. Tumor Suppressor Functions of miR-133a in Colorectal Cancer. Mol Cancer Res 2013; 11: 1051-1060.
131. Luu C, Heinrich EL, Duldulao M, et al. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells. PLoS One 2013; 8: e70604.
132. Chen MB, Wei MX, Han JY, et al. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer cells. Cell Signal 2013; 10.
133. Wang P, Zou F, Zhang X, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009; 69: 8157-8165.
134. Yuan K, Xie K, Fox J, et al. Decreased Levels of miR-224 and the Passenger Strand of miR-221 Increase MBD2, Suppressing Maspin and Promoting Colorectal Tumor Growth and Metastasis in Mice. Gastroenterology 2013; 145: 853-864.
135. Iliou MS, da Silva-Diz V, Carmona FJ, et al. Impaired DICER1 function promotes stemness and metastasis in colon cancer. Oncogene 2013; 10.
136. Wang J, Wang Q, Liu H, et al. MicroRNA expression and its implication for the diagnosis and therapeutic strategies of gastric cancer. Cancer Lett 2010; 297: 137-143.
137. Desai KV, Xiao N, Wang W, et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A 2002; 99: 6967-6972.
138. LaConti JJ, Shivapurkar N, Preet A, et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011; 6: e20687.